Eczematoid paradoxical reaction in psoriasis patients following secukinumab

Eczematoid paradoxical reaction in psoriasis patients following secukinumab

Saved in:

Bibliographic Details
Main Authors:	Heng Zhang, Yan Zhao, Lingxia Wang, Zhanglei Mu, Xiaoyang Liu, Jianzhong Zhang, Lin Cai, Lishao Guo
Format:	Article
Language:	English
Published:	Wolters Kluwer 2025-04-01
Series:	Chinese Medical Journal
Online Access:	http://journals.lww.com/10.1097/CM9.0000000000003505
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Secukinumab-induced Crohn’s disease in a psoriasis patient: a case report highlighting paradoxical reactions to IL-17 inhibition
by: Huiling Dai, et al.
Published: (2025-07-01)

Secukinumab: In psoriasis and beyond
by: Aditya K. Bubna, et al.
Published: (2025-01-01)

Tapinarof inhibits psoriatic inflammation through inducing tolerogenic dendritic cells and Foxp3+ Tregs
by: Yan Zhao, et al.
Published: (2024-12-01)

Awareness of the Risk of Paradoxical Psoriasis in Patients with SAPHO Syndrome Undergoing Treatment with Secukinumab: A Case Series
by: Xu C, et al.
Published: (2025-03-01)

Experience of using secukinumab in the treatmentof patients with psoriasis
by: N. V. Zilberberg, et al.
Published: (2021-11-01)

Position Statement on Secukinumab in the Management of Plaque Psoriasis: The Malaysian Perspective
by: Asmah Johar, et al.
Published: (2019-01-01)

Successful Treatment with Secukinumab in a Psoriasis Patient on Hemodialysis
by: Xiao Y, et al.
Published: (2025-07-01)

Successful Treatment of Pediatric Generalized Pustular Psoriasis with Secukinumab
by: Yu K, et al.
Published: (2025-01-01)

Hypoxia-induced RHCG as a key regulator in psoriasis and its modulation by secukinumab
by: Shun Guo, et al.
Published: (2025-06-01)

Case Report: Secukinumab for the treatment of severe psoriasis in a patient with hereditary hemochromatosis
by: Yingzhe Yu, et al.
Published: (2025-08-01)

A case report of allergic eczematoid dermatitis around hemodialysis access due to iodine-containing disinfectant
by: Xiaomei Lu, et al.
Published: (2025-07-01)

Complete treatment experience on psoriasis patients with secukinumab in real practice in Krasnodar region
by: L. S. Kruglova, et al.
Published: (2021-06-01)

Efficacy of Secukinumab in Management of Erythrodermic Psoriasis: A Study in Treatment-naïve Cases
by: Aradhana Rout, et al.
Published: (2025-07-01)

Fractional Carbon Dioxide Laser Combined with Secukinumab in the Treatment of Refractory Psoriasis Lesions on the Lower Legs
by: Ye H, et al.
Published: (2024-12-01)

Treatment of severe plaque psoriasis complicated with HIV infection using secukinumab: a case report
by: JING Xiaolei, et al.
Published: (2025-04-01)

Secukinumab treatment of IgA nephropathy manifested by psoriasis complicated with nephrotic syndrome： a case report
by: Xie Ting-ting, et al.
Published: (2025-03-01)

Secukinumab treatment of IgA nephropathy manifested by psoriasis complicated with nephrotic syndrome： a case report
by: Xie Ting-ting, et al.
Published: (2025-03-01)

Efficacy and Safety of Adalimumab and Secukinumab in Erythrodermic Psoriasis: A Single Centre Retrospective Study
by: Yachen Wang, et al.
Published: (2025-07-01)

Personalized Secukinumab Treatment in Patients with Plaque Psoriasis Using Model-Informed Precision Dosing
by: Karine Rodriguez-Fernandez, et al.
Published: (2024-12-01)

Annular pustular psoriasis: A heterogeneous subtype of generalized pustular psoriasis
by: Xiaoyan Wu, et al.
Published: (2025-07-01)

Secukinumab: A safe option to treat psoriasis and psoriatic arthritis in the presence of interstitial lung disease
by: Raja Natarajan
Published: (2019-01-01)

Successful treatment of generalized pustular psoriasis during pregnancy with secukinumab in a patient hypersensitive to spesolimab: a case report
by: Shuang Zhang, et al.
Published: (2025-12-01)

Behcet’s-like disease induced by secukinumab in a patient with psoriasis: a case report and literature review
by: Kecen Liu, et al.
Published: (2024-12-01)

Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain
by: Susanne Hartz, et al.
Published: (2020-08-01)

Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection
by: Matteo Megna, et al.
Published: (2022-07-01)

Long-Term efficacy and safety analysis of secukinumab in the treatment of pediatric generalized pustular psoriasis: a real-world study
by: Lu Xing, et al.
Published: (2025-12-01)

Nonscrapable yeast: A case of chronic hyperplastic candidiasis following secukinumab therapy
by: Gabriela A. Duchesne, BS, et al.
Published: (2025-09-01)

Granuloma Annulare in the Setting of Secukinumab
by: Matthew L. Clark, et al.
Published: (2018-01-01)

Treatment of Psoriasis with II-17 Inhibitors: Comparison of Long-Term Effectiveness and Drug Survival of Secukinumab vs Ixekizumab in Real-World Practice
by: Lam J, et al.
Published: (2025-03-01)

Corrigendum to “A Rare Case of New-Onset Ulcerative Colitis following Initiation of Secukinumab”
by: Ted George Achufusi, et al.
Published: (2019-01-01)

A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis
by: Dean Ehrlich, et al.
Published: (2018-01-01)

Relapsing Polychondritis following Treatment with Secukinumab for Ankylosing Spondylitis: Case Report and Review of the Literature
by: Alexander Zheutlin, et al.
Published: (2018-01-01)

WHAT ADVERSE REACTIONS TO BIOLOGICAL AGENTS ARE PARADOXICAL?
by: Yu. V. Muravyev
Published: (2018-09-01)

Secukinumab in refractory non-infectious anterior uveitis
by: Otto M. Olivas-Vergara, et al.
Published: (2025-02-01)

Clinical efficacy of secukinumab in treating sleep disorders in psoriatic patients
by: ZHOU Cuimei, et al.
Published: (2025-07-01)

Severe paradoxical generalized pustular psoriasis induced by adalimumab biosimilar successfully treated with brodalumab
by: Angela Fico, et al.
Published: (2025-05-01)

Real-Life Data of Secukinumab in Patients with Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis: Patient Baseline Characteristics Data from the PROMPT Study
by: Ploysyne Rattanakaemakorn, et al.
Published: (2024-11-01)

Genetic Susceptibility and Predictors of Paradoxical Reactions in Buruli Ulcer.
by: Yves Thierry Barogui, et al.
Published: (2016-04-01)

Novel Presentation of Terminal Ileitis Associated with Secukinumab Therapy
by: Aciel Ahmed Shaheen, et al.
Published: (2021-01-01)

Experience in using secukinumab in patients with axial psoriatic arthritis
by: E. E. Gubar, et al.
Published: (2020-11-01)